One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Expanding Current Approaches to Solve the Opioid Crisis
Carlos Blanco, MD, PhD1; Melanie M. Wall, PhD2; Mark Olfson, MD, MPH2
doi : 10.1001/jamapsychiatry.2021.3136
JAMA Psychiatry. 2022;79(1):5-6
Right-Based Mental Health Care—Advantages of Tax-Financed Universal Mental Health Care
Merete Nordentoft, DrMSc1,2; Mette Falkenberg Krantz, PhD1,2; Ida Hageman, DrMSc3
doi : 10.1001/jamapsychiatry.2021.3167
JAMA Psychiatry. 2022;79(1):7-8
Testing for Antisuicidal Effects of Lithium Treatment
Ross J. Baldessarini, MD1,2; Leonardo Tondo, MS, MD1,3
doi : 10.1001/jamapsychiatry.2021.2992
JAMA Psychiatry. 2022;79(1):9-10
Increasing the Impact of Prevention of Depression—New Opportunities
Pim Cuijpers, PhD1; Charles F. Reynolds III, MD2
doi : 10.1001/jamapsychiatry.2021.3153
JAMA Psychiatry. 2022;79(1):11-12
Effect of Pain Reprocessing Therapy vs Placebo and Usual Care for Patients With Chronic Back Pain
Yoni K. Ashar, PhD1,2,3; Alan Gordon, LCSW4; Howard Schubiner, MD5,6; Christie Uipi, LCSW4; Karen Knight, MD7; Zachary Anderson, BS2,3,8; Judith Carlisle, MA2,3,9; Laurie Polisky, BA2,3; Stephan Geuter, PhD2,3,10; Thomas F. Flood, MD, PhD11; Philip A. Kragel, PhD2,3,12; Sona Dimidjian, PhD2,13; Mark A. Lumley, PhD14; Tor D. Wager, PhD2,3,15
doi : 10.1001/jamapsychiatry.2021.2669
JAMA Psychiatry. 2022;79(1):13-23
Chronic back pain (CBP) is a leading cause of disability, and treatment is often ineffective. Approximately 85% of cases are primary CBP, for which peripheral etiology cannot be identified, and maintenance factors include fear, avoidance, and beliefs that pain indicates injury.
Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder
Ira R. Katz, MD, PhD1,2; Malcolm P. Rogers, MD3,4; Robert Lew, PhD5,6; Soe Soe Thwin, PhD6,7; Gheorghe Doros, PhD5,6; Eileen Ahearn, MD, PhD8,9; Michael J. Ostacher, MD, MPH, MMSc10,11; Lynn E. DeLisi, MD12; Eric G. Smith, MD, MPH, PhD13,14; Robert J. Ringer, PharmD15; Ryan Ferguson, MPH, ScD5,16; Brian Hoffman, MD17; James S. Kaufman, MD18,19; Julie M. Paik, MD, ScD20; Chester H. Conrad, MD, PhD16,21; Erika F. Holmberg, MPH5; Tamara Y. Boney, MS, CCRS1; Grant D. Huang, MPH, PhD22; Matthew H. Liang, MD, MPH5,23,24; for the Li+ plus Investigators
doi : 10.1001/jamapsychiatry.2021.3170
JAMA Psychiatry. 2022;79(1):24-32
Suicide and suicide attempts are persistent and increasing public health problems. Observational studies and meta-analyses of randomized clinical trials have suggested that lithium may prevent suicide in patients with bipolar disorder or depression.
Prevention of Incident and Recurrent Major Depression in Older Adults With Insomnia
Michael R. Irwin, MD1,2; Carmen Carrillo, MA, MHS1; Nina Sadeghi, BS1; Martin F. Bjurstrom, MD1; Elizabeth C. Breen, PhD1,2; Richard Olmstead, PhD1,2
doi : 10.1001/jamapsychiatry.2021.3422
JAMA Psychiatry. 2022;79(1):33-41
Older adults with insomnia have a high risk of incident and recurrent depression. Depression prevention is urgently needed, and such efforts have been neglected for older adults.
Association of Single-blind Placebo Run-in Periods With the Placebo Response in Randomized Clinical Trials of Antidepressants
Amelia J. Scott, PhD1,2; Louise Sharpe, PhD1; Veronica Quinn, PhD2; Ben Colagiuri, PhD1
doi : 10.1001/jamapsychiatry.2021.3204
JAMA Psychiatry. 2022;79(1):42-49
Single-blind placebo run-in (PRI) periods are common in randomized clinical trials (RCTs) of treatment for depression. They aim to increase sensitivity to detect drug effects; however, the association of PRI periods with study outcomes remains unclear. This is concerning given the costs of PRI periods to patients and investigators.
Association of Comorbid Behavioral and Medical Conditions With Cannabis Use Disorder in Pregnancy
Angélica Meinhofer, PhD1; Jesse M. Hinde, PhD2; Katherine M. Keyes, PhD, MPH3; Claudia Lugo-Candelas, PhD4
doi : 10.1001/jamapsychiatry.2021.3193
JAMA Psychiatry. 2022;79(1):50-58
Prenatal cannabis use continues to increase, yet studies of the demographic, psychiatric, and medical characteristics associated with cannabis use in pregnancy are limited by size and use of self-report, and often do not consider cannabis use disorder (CUD) or concomitant substance use disorders (SUDs). Understanding the factors associated with CUD in pregnancy is paramount for designing targeted interventions.
Comparing Copy Number Variations in a Danish Case Cohort of Individuals With Psychiatric Disorders
Xabier Calle Sánchez, MS1,2; Dorte Helenius, PhD1,2; Jonas Bybjerg-Grauholm, PhD2,3; Carsten Pedersen, PhD2,4,5,6; David M. Hougaard, MD2,3; Anders D. Børglum, PhD2,7,8; Merete Nordentoft, PhD2,9,10; Ole Mors, MD2,11; Preben B. Mortensen, DrMedSc2,4,7; Daniel H. Geschwind, MD12,13,14,15,16; Simone Montalbano, MS1,2; Armin Raznahan, MD17; Wesley K. Thompson, PhD2,18; Andrés Ingason, PhD1,2,19; Thomas Werge, PhD1,2,10,19
doi : 10.1001/jamapsychiatry.2021.3392
JAMA Psychiatry. 2022;79(1):59-69
Although the association between several recurrent genomic copy number variants (CNVs) and mental disorders has been studied for more than a decade, unbiased, population-based estimates of the prevalence, disease risks and trajectories, fertility, and mortality to contrast chromosomal abnormalities and advance precision health care are lacking.
Addressing Structural Racism in Psychiatry With Steps to Improve Psychophysiologic Research
Julianne L. Price, PhD1; Marino A. Bruce, PhD2; Bryon Adinoff, MD3
doi : 10.1001/jamapsychiatry.2021.2663
JAMA Psychiatry. 2022;79(1):70-74
The American Medical Association has acknowledged the public health threat posed by racism in medicine. While clinicians in psychiatry have echoed the sentiment, the research community has largely been silent. Current understanding of the biological domains that underlie psychiatric disorders was historically established by studying White populations, often leaving widely used treatments ineffective for Asian, Black, Hispanic, Indigenous, and other racial and ethnic minority individuals. This article addresses how undersampling of racial and ethnic minority individuals has led to overgeneralized physiological findings, the implications for development of psychiatric treatments, and steps to improve service to racially diverse communities.
Computational Psychiatry Across Species to Study the Biology of Hallucinations
Katharina Schmack, MD, PhD1,2; Torben Ott, PhD3,4; Adam Kepecs, PhD3,4
doi : 10.1001/jamapsychiatry.2021.3200
JAMA Psychiatry. 2022;79(1):75-76
Long-term Arrhythmia Detection Using an Implantable Loop Recorder in Patients Receiving Psychotropic Medication
Julie Nordgaard, MD, PhD, DMsc1; Thomas Melchior, MD, PhD2
doi : 10.1001/jamapsychiatry.2021.2809
JAMA Psychiatry. 2022;79(1):77-78
Deletion of Loss-of-Function–Intolerant Genes and Risk of 5 Psychiatric Disorders
Michael Wainberg, PhD1; Daniele Merico, PhD2,3; Guillaume Huguet, PhD4,5; Mehdi Zarrei, PhD3,6; Sebastien Jacquemont, PhD4,5; Stephen W. Scherer, PhD3,6,7,8; Shreejoy J. Tripathy, PhD1,9,10,11
doi : 10.1001/jamapsychiatry.2021.3211
JAMA Psychiatry. 2022;79(1):78-81
Insights Into Mixing Fentanyl and Benzodiazepines From Canadian Drug Seizures
Bryce Pardo, PhD1
doi : 10.1001/jamapsychiatry.2021.3292
JAMA Psychiatry. 2022;79(1):81-83
Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia
Mark Abie Horowitz, PhD1; Alex Macaulay, MBBS2; David Taylor, PhD3
doi : 10.1001/jamapsychiatry.2021.3400
JAMA Psychiatry. 2022;79(1):83-85
Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia
Mikkel Højlund, MD1; Peter M. Haddad, MD2; Christoph U. Correll, MD3
doi : 10.1001/jamapsychiatry.2021.3452
JAMA Psychiatry. 2022;79(1):85-86
Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia—Reply
Stefan Leucht, MD1,2; Spyridon Siafis, MD1; John M. Davis, MD3,4
doi : 10.1001/jamapsychiatry.2021.3403
JAMA Psychiatry. 2022;79(1):86-87
